124 related articles for article (PubMed ID: 26011703)
1. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.
Nakao K; Tanaka S; Miura T; Sato K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
Cancer Sci; 2015 Aug; 106(8):1016-22. PubMed ID: 26011703
[TBL] [Abstract][Full Text] [Related]
2. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
5. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption.
Lin ZZ; Chou CH; Cheng AL; Liu WL; Chia-Hsien Cheng J
Int J Cancer; 2014 Jul; 135(2):492-501. PubMed ID: 24375034
[TBL] [Abstract][Full Text] [Related]
11. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
Emanuel S; Rugg CA; Gruninger RH; Lin R; Fuentes-Pesquera A; Connolly PJ; Wetter SK; Hollister B; Kruger WW; Napier C; Jolliffe L; Middleton SA
Cancer Res; 2005 Oct; 65(19):9038-46. PubMed ID: 16204078
[TBL] [Abstract][Full Text] [Related]
12. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
13. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
[TBL] [Abstract][Full Text] [Related]
14. Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways.
Zhang C; Wu X; Zhang M; Zhu L; Zhao R; Xu D; Lin Z; Liang C; Chen T; Chen L; Ren Y; Zhang J; Qin N; Zhang X
PLoS One; 2013; 8(6):e65264. PubMed ID: 23755206
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
[TBL] [Abstract][Full Text] [Related]
16. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor.
Xie F; Zhu H; Zhang H; Lang Q; Tang L; Huang Q; Yu L
Eur J Med Chem; 2015 Jan; 89():310-9. PubMed ID: 25462247
[TBL] [Abstract][Full Text] [Related]
19. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
20. [Induction of necrosis in the hepatocellular carcinoma HepG2 xenografts treated with SOM230].
Xie Y; Chen S; Wang CH; Tang CW
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):759-64. PubMed ID: 19874692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]